Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib with G-CSF for Stem Cell Mobilization in Multiple Myeloma
NCT02220608Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of bortezomib in multiple myeloma (MM) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Maximum tolerated dose of bortezomib when given with G-CSF at 12 months. Started Feb 2015; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02220608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220608.